Gao Xinran, Jiang Jingting
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Jiangsu Engineering Research Center for Tumor lmmunotherapy, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Front Immunol. 2024 Mar 28;15:1359029. doi: 10.3389/fimmu.2024.1359029. eCollection 2024.
Serving as a pivotal immunotherapeutic approach against tumors, anti-PD-1/PD-L1 therapy amplifies the immune cells' capability to eliminate tumors by obstructing the interaction between PD-1 and PD-L1. Research indicates that immune checkpoint inhibitors are effective when a patient's gut harbors unique beneficial bacteria. As such, it has further been revealed that the gut microbiome influences tumor development and the efficacy of cancer treatments, with metabolites produced by the microbiome playing a regulatory role in the antitumor efficacy of Immune checkpoint inhibitors(ICBs). This article discusses the mechanism of anti-PD-1 immunotherapy and the role of intestinal flora in immune regulation. This review focuses on the modulation of intestinal flora in the context of PD-1 immunotherapy, which may offer a new avenue for combination therapy in tumor immunotherapy.
作为一种关键的抗肿瘤免疫治疗方法，抗PD-1/PD-L1疗法通过阻断PD-1与PD-L1之间的相互作用，增强免疫细胞消除肿瘤的能力。研究表明，当患者肠道中存在独特的有益细菌时，免疫检查点抑制剂是有效的。因此，进一步揭示了肠道微生物群会影响肿瘤发展和癌症治疗效果，微生物群产生的代谢产物在免疫检查点抑制剂（ICB）的抗肿瘤疗效中发挥调节作用。本文讨论了抗PD-1免疫治疗的机制以及肠道菌群在免疫调节中的作用。本综述重点关注在PD-1免疫治疗背景下对肠道菌群的调节，这可能为肿瘤免疫治疗的联合疗法提供新途径。
